603259 药明康德
2025/06 - 中期2024/122023/122022/122021/12

盈利能力分析
净资产收益率 ROE (%)14.44316.61518.89020.71814.361
总资产报酬率 ROA (%)10.43112.27413.88714.71210.052
投入资产回报率 ROIC (%)12.44114.38916.07417.20911.686

边际利润分析
销售毛利率 (%)44.44941.47941.17937.29636.285
营业利润率 (%)47.74729.51029.43027.06726.363
息税前利润/营业总收入 (%)48.62527.40228.49226.35126.633
净利润/营业总收入 (%)41.63824.38224.04622.62122.425

收益指标分析
经营活动净收益/利润总额(%)68.481103.11498.31289.97571.944
价值变动净收益/利润总额(%)35.1966.8561.6579.02220.993
营业外收支净额/利润总额(%)-0.239-0.350-0.341-0.318-0.368

偿债能力分析
流动比率 (X)2.0762.3842.0621.6551.693
速动比率 (X)1.7272.0521.7411.2641.238
资产负债率 (%)27.93326.44324.64027.46029.695
带息债务/全部投入资本 (%)11.73210.0899.43711.85911.730
股东权益/带息债务 (%)728.141861.022914.681705.652701.827
股东权益/负债合计 (%)255.872276.046303.673262.277235.136
利息保障倍数 (X)49.047-13.669-33.994-41.82272.544

营运能力分析
应收账款周转天数 (天)64.83772.71861.90648.44765.110
存货周转天数 (天)97.76579.44878.92884.420105.971